Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$13.8M
2 rounds on record
Latest round
$13.8M
Venture round · Nov 2025 · 11 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
11 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Nov 10, 2025 Raised a round Venture round $13.8M · SEC Form D Aug 18, 2021 Took on debt financing $9.9M · SEC Form D 2020 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Nov 2025 $13.8M — SEC Form D
Debt Financing Aug 2021 $9.9M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Kamal Therapeutics, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Mark de SouzaExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
PulmocideVenture round $52M · 3 yr ago • 201-500 employees
Pulmocide is a biotechnology company developing novel inhaled medicines for pulmonary aspergillosis and other hard-to-treat respiratory…
Plasana MédicalFounded 2022
Innovative medical device to treat chronic wounds. DISCOVER.
Trellis BioscienceSeries C $9M · 3 mo ago
Trellis Bioscience is developing native human antibodies to disrupt bacterial biofilms and address difficult-to-treat infections.
Lassogen, Inc.Seed · 6 yr ago • Founded 2019 • 11-50 employees
Lassogen is developing a new therapeutic modality based on lasso peptides that we are programming to treat difficult diseases such as…
Pyxis OncologyVenture round $172.5M · 5 yr ago • Founded 2018
Charting a course to therapeutics for difficult-to-treat cancers.
Kinaset TherapeuticsSeries B $103M · 9 mo ago • Founded 2020 • 51-200 employees
DEVELOPING INHALED THERAPEUTICS IN RESPIRATORY DISEASES. Kinaset is developing KN-002 to treat all patients with severe asthma regardless…

Overview

Developing intravenous recombinant human decorin to treat dystrophic epidermis bullosa.. Kamal Therapeutics, Inc.

People

Mark de Souza
Executive Officer, Director
Philip Reilly
Director
John Parker
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Hingham United States
HQ
50-200 est. staff

Financials

Total raised
$23.8M
Latest round
Venture - Series Unknown
Funding rounds
2
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $13.8M Details
Debt Financing 2021 $9.9M Details